As newborn screening and rapid DNA sequencing become routine, we are poised to catch and treat inherited diseases at their ...

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor ...

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

Dr. Tejal Aslesh Tailor is an accomplished neuroscientist and molecular biologist with years of expertise in preclinical ...

This first-in-human trial is testing a highly unconventional method: delivering fat-derived stem cells from the patient ...

MarkHerz Inc., a biotechnology company specializing in AAV-based gene therapies targeting cardiovascular and metabolic diseases, announced that it has signed a Memorandum of Understanding (MOU) on May ...

Neuroscientists can now make precise genetic tweaks to the neurons that are most affected by brain diseases such as Parkinson ...

Panelists discuss how the future of polycythemia vera (PV) management will be shaped by advancements in targeted therapies, ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

The clinical trial tech companies Medidata and Medable are both taking to the floor of the American Society of Clinical ...

AMT-130 has been granted the FDA's Regenerative Medicine Advance Therapy (RMAT) designation and Breakthrough Therapy designation, the first therapy for Huntington's disease to receive an RMAT ...

STEMCELL Technologies, Canada's largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based ne ...